Evaluation of efficacy and safety of Intravitreal bevacizumab versus intravitreal bevacizumab combined with juxtascleral anecortave acetate for the treatment exudative age-related macular degeneration - IVB JSA

IVERSITA DEGLI STUDI DI UDINE0 个研究点开始时间: 2007年3月15日最近更新: 2012年3月19日

试验速览

暂无简介。

•Patients who are 50 year old or older. Patients willing to sign a written informed consent. Patients with age-related macular degeneration and subfoveal choroidal neovascularization, primary when the lesion characteristics controindicate standard treatments, i.e. large occult neovascularization, greater than 4 disc areas or recurrent after standard treatment increase of lesione size by 10 and/or visual loss equal or greater than 2 ETDRS lines after photodynamic therapy with verteporfin
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•Concomitant ocular disease in the study eye that could affect visual acuity Prior treatment of the study eye with photodinamic therapy, laser photocoagulation within 90 days preceeding day 1 or any other experimental treatmentPrior ocular surgery within 60 days preceeding baseline Uncontrolled blood pressure Previous stroke or myocardial infarction

发起方

IVERSITA DEGLI STUDI DI UDINE